MD Anderson Cancer Center

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Retains its Position as New Jersey's Only National Cancer Institute-Designated Comprehensive Cancer Center

Retrieved on: 
Tuesday, March 5, 2024
FACS, Rutgers University, NCI, Education, Immunotherapy, Physician, RWJBarnabas Health, Health, Metastasis, NCI-designated Cancer Center, Princeton University, National Cancer Institute, Cooper University Hospital, Medicine, Patient, MD Anderson Cancer Center, Congress, Disease, Genomics, Ludwig Cancer Research, Research, Cancer, Partnership, Pharmaceutical industry

NEW BRUNSWICK, N.J., March 5, 2024 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey, together with RWJBarnabas Health, the state's leading cancer center and only Comprehensive Cancer Center as recognized by the National Cancer Institute (NCI), has scored in the "exceptional" range and was redesignated by the National Cancer Institute, placing it among the top cancer centers reviewed in 2023.

Key Points: 
  • NEW BRUNSWICK, N.J., March 5, 2024 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey, together with RWJBarnabas Health, the state's leading cancer center and only Comprehensive Cancer Center as recognized by the National Cancer Institute (NCI), has scored in the "exceptional" range and was redesignated by the National Cancer Institute, placing it among the top cancer centers reviewed in 2023.
  • This redesignation ensures that Rutgers Cancer Institute maintains its "Comprehensive Cancer Center" status to support the continuation of outstanding world class research and comprehensive care.
  • "For decades, Rutgers Cancer Institute has been a lifeline for those battling the cruel and relentless disease of cancer.
  • As the only NCI-Designated Comprehensive Cancer Center, Rutgers Cancer Institute is essential to the health of the people of our state and the advancement of cancer research nationally," says Congressman Frank Pallone.

Horizon CME Brings Best of ASCO® to San Francisco, Dallas, Phoenix and Los Angeles

Retrieved on: 
Wednesday, February 28, 2024
MD Anderson Cancer Center, Physician, Pharmacist, Annual general meeting, Convention center, Society, University, Mayo Clinic, Clinical professor, USC, CME, Medicine, Pharmaceutical industry

CLACKAMAS, Ore., Feb. 28, 2024 /PRNewswire/ -- Horizon CME will host Best of ASCO® 2024 programs in San Francisco, Dallas, Phoenix and Los Angeles.

Key Points: 
  • CLACKAMAS, Ore., Feb. 28, 2024 /PRNewswire/ -- Horizon CME will host Best of ASCO® 2024 programs in San Francisco, Dallas, Phoenix and Los Angeles.
  • These in-person conferences will bring the most recent oncology scientific findings to physicians, pharmacists and allied health providers in these regions.
  • Best of ASCO® is an officially licensed program of the American Society of Clinical Oncology® (ASCO®), the foremost professional organization representing physicians of all oncology subspecialties.
  • The Best of ASCO® Phoenix will be held July 20 - 21, 2024, at the Westin Kierland Hotel in Scottsdale, Ari.

Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Research Examining the High Rates of Re-Operations Following Breast-Conserving Surgeries and the Associated Increased Healthcare Costs

Retrieved on: 
Tuesday, February 20, 2024
Woman, Perimeter, BCS, University, OTC, Surgeon, PINK, Surgical oncology, Risk, MD Anderson Cancer Center, Attention, PMID, Medicare, Mastectomy, Conversion, Patient, Research

The results of our study demonstrate that high reoperation rates after breast-conserving surgery persist and are correlated with elevated risks and adverse outcomes for patients.

Key Points: 
  • The results of our study demonstrate that high reoperation rates after breast-conserving surgery persist and are correlated with elevated risks and adverse outcomes for patients.
  • I believe that these data underscore the need for new approaches to address high reoperation rates, including better methods of margin assessment for surgeons."
  • Funding to support this research was provided, in part, by Perimeter Medical Imaging AI, Inc.
    1 Kim Y, Ganduglia-Cazaban C, Tamirisa N, Lucci A, Krause TM.
  • Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery.

Roberts Markland LLP Welcomes Former United States District Judge Vanessa D. Gilmore to their Growing Team

Retrieved on: 
Thursday, February 8, 2024
MD Anderson Cancer Center, Education, Museum, University of Houston, Texas Children's Hospital, University, Mental health, Hospital, Knowledge, Practice of law

HOUSTON, Feb. 8, 2024 /PRNewswire/ -- Roberts Markland LLP , a leading law firm renowned for its commitment to legal excellence and community engagement, proudly announces the addition of former United States District Judge Vanessa D. Gilmore to its talented team.

Key Points: 
  • HOUSTON, Feb. 8, 2024 /PRNewswire/ -- Roberts Markland LLP , a leading law firm renowned for its commitment to legal excellence and community engagement, proudly announces the addition of former United States District Judge Vanessa D. Gilmore to its talented team.
  • "Judge Gilmore joining Roberts Markland is a significant milestone for our firm," said Sean Roberts, Partner at Roberts Markland.
  • In 1994, when Judge Gilmore was sworn in, she became the youngest sitting federal judge in the nation.
  • Judge Gilmore's decision to join Roberts Markland is a testament to the firm's stellar reputation and commitment to making a difference.

NEW DATA: 70% OF AMERICANS UNAWARE OF COMMON VASCULAR DISEASE THAT IS ONE OF THE LEADING CAUSES OF AMPUTATION

Retrieved on: 
Thursday, February 8, 2024
Pulse, Interventional radiology, Health equity, SCAI, Society for Vascular Surgery, Pain, Peripheral artery disease, MD Anderson Cancer Center, Prevalence, Interventions, SIR, University, Heart, Health, Amputation, Society, Diabetes, Heated tobacco product, Smoker, Risk, Patient, Leg, Rest, Vascular disease, Society of Interventional Radiology, PAD, Walking, MBA, Association of Black Cardiologists, Doctor of Philosophy

WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- According to a new national survey released today by the PAD Pulse Alliance, 70% of Americans are unaware of peripheral artery disease (PAD) – the most common vascular disease in which leg arteries become narrowed, reducing or cutting off blood flow, contributing to 400 amputations performed each day in the United States. The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities. Yet among Black and Hispanic adults, nearly 80% report never having a doctor or healthcare provider discuss PAD with them – underscoring the need to start the conversation.

Key Points: 
  • The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities.
  • That's why we're encouraging anyone with leading risk factors, diabetes, high blood pressure and use of tobacco products, to know your 'three for PAD' and talk to your doctor."
  • Data from the PAD Pulse Alliance survey highlights a disconnect among people between the risk factors and their personal perceived risk of PAD.
  • Nearly eight in 10 Black and Hispanic never had a doctor or healthcare provider talk with them about PAD.

Kemper Names Dr. Suzet McKinney of Sterling Bay to Board of Directors, Announces Retirement of Director Christopher Sarofim

Retrieved on: 
Wednesday, February 7, 2024
Professional Services, Insurance, Finance, Principal, Policy, Public, KMPR, MD Anderson Cancer Center, Brandeis University, Ecosystem, Public health, Advisory Committee, Organization, Kemper Corporation, Baylor College of Medicine, Wintrust Financial, Corporation, McKinney, Texas, Trustee, University, Benedictine University, Chicago school, Management

Kemper Corporation (NYSE: KMPR) announced that its Board of Directors has elected Dr. Suzet M. McKinney as a Director, effective February 7.

Key Points: 
  • Kemper Corporation (NYSE: KMPR) announced that its Board of Directors has elected Dr. Suzet M. McKinney as a Director, effective February 7.
  • The Board also announced that Christopher B. Sarofim has informed the Board of his intention to retire as a director at the end of his current term, expiring May 1, 2024.
  • Prior to Sterling Bay, she held a number of senior leadership roles in public health and policy administration.
  • “We’re pleased to welcome Suzet to our board,” said Joseph P. Lacher, Jr., President, CEO and Chairman of Kemper’s Board of Directors.

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

Retrieved on: 
Wednesday, February 7, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Acute myeloid leukemia, Permeability, Patient, ASCO, MD Anderson Cancer Center, AML, Myelodysplastic syndrome, Marketing, PEG, MDS, DDS, Blood, Spacecraft, Colorectal cancer, University, Cancer, Atomic mass

in 2024, we are excited to share our latest development status.

Key Points: 
  • in 2024, we are excited to share our latest development status.
  • A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States.
  • Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
  • On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.

PRISM MarketView Marks World Cancer Day

Retrieved on: 
Thursday, February 1, 2024
CONNECT, Melanoma, GBM, AIM, University, Breast, Prostate cancer, Acute myeloid leukemia, Renal cell carcinoma, Research, Prostate, Pancreatic cancer, Janssen Pharmaceuticals, Therapy, Patient, AML, ASCO, Temozolomide, PRISM, MD Anderson Cancer Center, FDA, Glioblastoma, Death, Rintatolimod, Glioma, Cancer, Olutasidenib, Pharmaceutical industry

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.

Key Points: 
  • NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.
  • To mark World Cancer Day , which will be held on February 4, PRISM MarketView highlights emerging companies working to improve the lives of cancer patients and their families by developing and commercializing innovative new treatments for cancer.
  • The company has entered a research agreement with the Johns Hopkins University School of Medicine for the development of Ivospemin.
  • Essa Pharma, a clinical stage pharmaceutical company, is focused on the development of small molecule drugs for the treatment of prostate cancer.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
Tuesday, January 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Dr. Samuel Lin Continues Partnership With Haute Beauty Network

Retrieved on: 
Friday, February 2, 2024
Partnership, Northwestern University, Certification, AAPS, ABMS, Plastic surgery, Knowledge, Science, Bachelor, Feinberg School of Medicine, Rhinoplasty, Division, Medical specialty, Internet celebrity, Expert, Plastic and Reconstructive Surgery, Biomedicine, Mentorship, Literature, MD Anderson Cancer Center, Elective surgery, Honors colleges and programs, Medical education, Harvard University, Harvard Medical School, Physician, Northwestern Memorial Hospital, Breast surgery, Biomedical engineering, Cure, Pearl, Editorial, Associate, University, Student, Editor-in-chief, Dentistry

NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts. Dr. Lin received his Bachelor's degree in Biomedical Engineering at Northwestern University and was enrolled in the Honors Program for Medical Education at Northwestern University, Feinberg School of Medicine, Chicago, Illinois. He then completed a five-year-residency in Otolaryngology-Head and Neck Surgery followed by a three-year-residency in Plastic and Reconstructive Surgery at Northwestern Memorial Hospital. This was followed by a one-year fellowship appointment in Microvascular Reconstructive Surgery at the world-renowned University of Texas M.D. Anderson Cancer Center in Houston, Texas. Throughout the course of his training, Dr. Lin gained state-of-the-art skills in a multitude of reconstructive and cosmetic procedures with his background in Head and Neck Surgery providing him with additional expertise in Plastic and Reconstructive Surgery. He has also been named a Top Influencer in #PlasticSurgery.

Key Points: 
  • Nose Expert from Boston, Dr. Samuel Lin, continues his partnership with Haute Beauty Network, now in his sixth year.
  • NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts.
  • Dr. Lin is board certified by both the American Board of Plastic Surgery and the American Board of Otolaryngology-Head and Neck Surgery.
  • Dr. Lin, his team, and his collaborators regularly publish scientific papers in the literature to further knowledge about plastic surgery and other topics.